Last reviewed · How we verify
fentanyl; naltrexone
At a glance
| Generic name | fentanyl; naltrexone |
|---|---|
| Sponsor | Alza Corporation, DE, USA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Naltrexone for Overdose Prevention (PHASE2, PHASE3)
- Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions (NA)
- Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation). (PHASE1)
- Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv) (PHASE1)
- Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers (PHASE1)
- A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fentanyl; naltrexone CI brief — competitive landscape report
- fentanyl; naltrexone updates RSS · CI watch RSS
- Alza Corporation, DE, USA portfolio CI